Repeat patient testing shows promise as a quality control method for veterinary hematology testing

© 2018 American Society for Veterinary Clinical Pathology.

Bibliographische Detailangaben
Veröffentlicht in:Veterinary clinical pathology. - 1975. - 47(2018), 2 vom: 23. Juni, Seite 252-266
1. Verfasser: Flatland, Bente (VerfasserIn)
Weitere Verfasser: Freeman, Kathleen P
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2018
Zugriff auf das übergeordnete Werk:Veterinary clinical pathology
Schlagworte:Comparative Study Journal Article Validation Study Advia 120 blood cell count canine impedance quality assurance
LEADER 01000naa a22002652 4500
001 NLM28162268X
003 DE-627
005 20231225032045.0
007 cr uuu---uuuuu
008 231225s2018 xx |||||o 00| ||eng c
024 7 |a 10.1111/vcp.12593  |2 doi 
028 5 2 |a pubmed24n0938.xml 
035 |a (DE-627)NLM28162268X 
035 |a (NLM)29505172 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Flatland, Bente  |e verfasserin  |4 aut 
245 1 0 |a Repeat patient testing shows promise as a quality control method for veterinary hematology testing 
264 1 |c 2018 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 11.10.2018 
500 |a Date Revised 10.12.2019 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2018 American Society for Veterinary Clinical Pathology. 
520 |a BACKGROUND: Repeat patient testing-based quality control (RPT-QC) is a potential method for veterinary laboratories (eg, that have a limited budget for quality commercial control material [QCM] or that wish to use material with a species-specific matrix) 
520 |a OBJECTIVES: To determine whether total error (TEa ), probability of error detection (Ped), and probability of false rejection (Pfr) similar to that achievable with QC materials can be controlled using RPT-QC METHODS: Control limits (WBC, RBC, HGB, HCT, MCV, and PLT) for the Advia 120 (n = 23) and scil Vet ABC (n = 22) were calculated using data from normal canine specimens from a routine caseload. Specimens were measured at accession and again after 24 hours. Control limits were validated using 23 additional canine specimens tested similarly. Achievable TEa, Ped, and Pfr were investigated using the Westgard EZRules3 and compared to those achievable with commercial QCM 
520 |a RESULTS: Theoretical performance of RPT-QC and commercial QCM-QC are similar for 1-3s with both n = 1 and 1-3s with n = 2 for all measurands and both instruments. Achievable TEa values for RPT-QC were close to ASVCP recommendations for most measurands; exceptions were PLT (both instruments) and WBC (scil Vet ABC) 
520 |a CONCLUSIONS: Repeat patient testing-based quality control advantages include a species-specific matrix, low-cost, and absence of QC material deterioration over time (since a fresh specimen is used each day). A potential disadvantage is daily access to normal canine specimens. A challenge is determining control limits, which has a subjective element. Further study is needed to confirm actual RPT-QC performance and to determine if RPT-QC with abnormal patient specimens is feasible 
650 4 |a Comparative Study 
650 4 |a Journal Article 
650 4 |a Validation Study 
650 4 |a Advia 120 
650 4 |a blood cell count 
650 4 |a canine 
650 4 |a impedance 
650 4 |a quality assurance 
700 1 |a Freeman, Kathleen P  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Veterinary clinical pathology  |d 1975  |g 47(2018), 2 vom: 23. Juni, Seite 252-266  |w (DE-627)NLM098159984  |x 1939-165X  |7 nnns 
773 1 8 |g volume:47  |g year:2018  |g number:2  |g day:23  |g month:06  |g pages:252-266 
856 4 0 |u http://dx.doi.org/10.1111/vcp.12593  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 47  |j 2018  |e 2  |b 23  |c 06  |h 252-266